Skip to main content
SpringerLink
Log in

Benign Prostatic Hyperplasia

  • Chapter
Fundamentals of Geriatric Medicine

  • 2022 Accesses

Abstract

Upon completion of the chapter, the student will be able to:

  1. 1.

    Describe the epidemiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) in older men.

  2. 2.

    Describe age-related changes of the prostate, and pathophysiology of BPH and LUTS.

  3. 3.

    Describe typical symptoms and signs of LUTS.

  4. 4.

    List steps in diagnostic evaluation of LUTS.

  5. 5.

    Discuss utility of urodynamic testing, and when to refer to a urologist.

  6. 6.

    List four main treatment approaches recommended for BPH, and discuss general treatment considerations.

  7. 7.

    Discuss pharmacology, dosage, and side effects of medications for treatment of BPH.

Material in this chapter is based on the following chapter in Cassel CK, Leipzig RM, Cohen HJ, Larson EB, Meier DE, eds. Geriatric Medicine: An Evidence-Based Approach, 4th ed. New York: Springer, 2003: DuBeau CE. Benign Prostatic Hyperplasia, pp. 755–768. Selections edited by Hans L. Stöhrer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Readings

  • Barry MJ, Fowler FJ Jr, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549–1557. The AUA symptom index is clinically sensible, reliable, valid and responsive. It is practical for use in practice and for inclusion in research protocols.

    PubMed  CAS  Google Scholar 

  • DuBeau CE. Benign prostatic hyperplasia. In: Cassel CK, Leipzig RM, Cohen HJ, et al., eds. Geriatric Medicine, 4th ed. New York: Springer, 2003:755–768.

    Google Scholar 

  • AUA Practice Guidelines Committee (2003). AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 203;170:530–547. A comprehensive review of the identification and management of BPH. It includes an intensive review of the randomized trials addressing the different treatment approaches.

    Article  Google Scholar 

References

  1. Schäfer W, Rubben H, Noppeney R, Deutz F-J. Obstructed and unobstructed prostatic obstruction: a plea for urodynamic objectivation of bladder outflow obstruction in benign prostatic hyperplasia. World J Urol 1989;6:198–203.

    Article  Google Scholar 

  2. Coolsaet BLRA, van Venrooij GEPM, Blok C. Prostatism: rationalization of urodynamic testing. World J Urol 1984;2:216–221.

    Article  Google Scholar 

  3. Abrams P. In support of pressure-flow studies for evaluating men with lower urinary tract symptoms. Urology 1994;44:153–155.

    Article  PubMed  CAS  Google Scholar 

  4. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33–50.

    Article  PubMed  CAS  Google Scholar 

  5. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474–479.

    PubMed  CAS  Google Scholar 

  6. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993;150:85–89.

    PubMed  CAS  Google Scholar 

  7. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991;145:405–409.

    PubMed  CAS  Google Scholar 

  8. Watanabe H. Natural history of benign prostatic hypertrophy. Ultrasound Med Biol 1986;12:567–571.

    Article  PubMed  CAS  Google Scholar 

  9. Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a 4-year, randomized trial comparing finasteride versus placebo. Urology 1999;54:662–669.

    Article  PubMed  CAS  Google Scholar 

  10. Dørflinger T, England DM, Madsen PO, Bruskewitz RC. Urodynamic and histological correlates of benign prostatic hyperplasia. J Urol 1988;140:1487–1490.

    PubMed  Google Scholar 

  11. Hinman F Jr. Point of view: capsular influence on benign prostatic hypertrophy. Urology 1986;28:347–350.

    Article  PubMed  Google Scholar 

  12. Chapple CR, Burt RP, Andersson PO, Greengrass P, Wyllie M, Marshall I. Alpha1-adrenoreceptor subtypes in the human prostate. Br J Urol 1994;74:585–589.

    PubMed  CAS  Google Scholar 

  13. Chapple CR, Smith D. The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. Br J Urol 1994;73:117–123.

    PubMed  CAS  Google Scholar 

  14. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. IV. Bladder outlet obstruction. J Urol 1993;150:1681–1695.

    PubMed  CAS  Google Scholar 

  15. AUA Practice Guidelines Committee (2003). AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 203;170:530–547.

    Article  Google Scholar 

  16. Bruskewitz RC, Larsen EH, Madsen PO, et al. 3 year followup of urinary symptoms after transurethral resection of the prostate. J Urol 1986;136:613–615.

    PubMed  CAS  Google Scholar 

  17. Jensen KM-E, Bruskewitz RC, Iversen P, Madsen PO. Significance of prostatic weight in prostatism. Urol Int 1983;38:173–178.

    PubMed  CAS  Google Scholar 

  18. Andersen JT, Nordling J. Prostatism II. The correlation between cystourethroscopic, cystometric, and urodynamic findings. Scand J Urol Nephrol 1980;14:23–27.

    PubMed  CAS  Google Scholar 

  19. Meyhoff HH, Hald T. Are doctors able to assess prostatic size? Scand J Urol Nephrol 1978;12:219–221.

    Article  PubMed  CAS  Google Scholar 

  20. Coolsaet B, Blok C. Detrusor properties related to prostatism. Neurourol Urodynam 1986;5:435–447.

    Article  Google Scholar 

  21. Barry MJ, Fowler FJ Jr, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549–1557.

    PubMed  CAS  Google Scholar 

  22. Root MT. Living with benign prostatic hypertrophy [letter]. N Engl J Med 1979;301:52.

    PubMed  CAS  Google Scholar 

  23. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1–13.

    Article  PubMed  CAS  Google Scholar 

  24. Kirby RS, McConnell JD. Fast Facts-Benign Prostatic Hyperplasia, 2nd ed. Oxford, UK: Health Press, 1997:29.

    Google Scholar 

  25. Lee M. Tamulosin for the treatment of benign prostatic hypertrophy. Ann Pharmacother 2000;34:188–199.

    Article  PubMed  CAS  Google Scholar 

  26. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185–1191.

    Article  PubMed  CAS  Google Scholar 

  27. Gormley GJ, Ng J, Cook T, Stoner E, Guess H, Walsh P. Effect of finasteride on prostate-specific antigen density. Urology 1994;43:53–59.

    Article  PubMed  CAS  Google Scholar 

  28. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557–563.

    Article  PubMed  CAS  Google Scholar 

  29. Wilt T, Ishani A, Stark G, Mac Donald R, Mulrow C, Lau J. Serenoa repens for benign prostatic hyperplasia (Cochrane Review). In: The Cochrane Library, issue 3. Oxford: Update Software, 2000.

    Google Scholar 

  30. Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55:533–539.

    Article  PubMed  CAS  Google Scholar 

  31. Wilt TJ, MacDonald R, Ishani A. Beta-sitosterols for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int 1999;83:976–983; see also: Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J. Beta-sitosterols for benign prostatic hyperplasia (Cochrane Review). In: The Cochrane Library, issue 3. Oxford: Update Software, 2000.

    Article  PubMed  CAS  Google Scholar 

  32. MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int 2000;85:836–841; see also: Wilt T, Ishani A, MacDonald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia (Cochrane Review). In: The Cochrane Library, issue 3. Oxford: Update Software, 2000.

    Article  PubMed  CAS  Google Scholar 

  33. McConnell JD. Medical management of benign prostatic hyperplasia with androgen suppression. Prostate Suppl 1990;3:49–59.

    Article  PubMed  CAS  Google Scholar 

  34. Eri LM, Tveter KJ. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol 1993;150:359–364.

    PubMed  CAS  Google Scholar 

  35. Jenkins BJ, Sharma P, Badenoch DF, Fowler CG, Blandy JP. Ethics, logistics and a trial of transurethral versus open prostatectomy. Br J Urol 1992;69:372–374.

    PubMed  CAS  Google Scholar 

  36. Libman E, Fichten CS. Prostatectomy and sexual function. Urology 1987;29:467–478.

    Article  PubMed  CAS  Google Scholar 

  37. Mebust WK, Holtgrewe HL, Cockett ATK, et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;141:243–247.

    PubMed  CAS  Google Scholar 

  38. Birch BR, Gelister JS, Parker CJ, Chave H, Miller RA. Transurethral resection of prostate under sedation and local anesthesia (sedoanalgesia). Urology 1991;38:113–118.

    Article  PubMed  CAS  Google Scholar 

  39. Neal DE. Prostatectomy: an open or closed case. Br J Urol 1990;66:449–454.

    PubMed  CAS  Google Scholar 

  40. Orandi A. Transurethral incision of the prostate (TUIP): 646 cases in 15 years—a chronological appraisal. Br J Urol 1985;57:703–707.

    PubMed  CAS  Google Scholar 

  41. Donovan JL, Peters TJ, Neal DE, et al. A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative management for lower urinary tract symptoms associated with benign prostatic enlargement: the ClasP study. J Urol 2000;164:65–70.

    Article  PubMed  CAS  Google Scholar 

  42. Carter A, Sells H, Speakman M, Ewings P, MacDonagh R, O’Boyle P. A prospective randomized controlled trial of hybrid laser treatment or transurethral section of the prostate, with a 1-year follow-up. BJU Int 1999;83:254–259.

    Article  PubMed  CAS  Google Scholar 

  43. Carter A, Sells H, Speakman M, Ewings P, O’Boyle P, MacDonagh R. Quality of life changes following KTP/Nd:YAG laser treatment of the prostate and TURP. Eur Urol 1999;36:92–98.

    Article  PubMed  CAS  Google Scholar 

  44. Jones JW, Carter A, Ewings P, O’Boyle PJ. An MRSA outbreak in a urology ward and its association with Nd:YAG coagulation laser treatment of the prostate. J Hosp Infect 1999;41:39–44.

    Article  PubMed  CAS  Google Scholar 

  45. Ogden CW, Reddy P, Johnson H, Ramsay JW, Carter SS. Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet 1993;341:14–17.

    Article  PubMed  CAS  Google Scholar 

  46. Bdesha AS, Bunce CJ, Kelleher JP, Snell ME, Vukusic J, Witherow RO. Transurethral microwave treatment for benign prostatic hypertrophy: a randomised controlled clinical trail. BMJ 1993;306:1293–1296.

    Article  PubMed  CAS  Google Scholar 

  47. Brehmer M, Wiskell H, Kinn A. Sham treatment compared with 30 or 60 min of thermotherapy for benign prostatic hyperplasia: a randomized study. BJU Int 1999;84:292a–296.

    Article  Google Scholar 

  48. Bruskewitz R, Issa M, Roehrborn C, et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998;159:1588–1594.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Emergency Medicine, Coney Island Hospital, New York City Health and Hospitals Corporation, Brooklyn, NY, 11235, USA

    Hans L. Stöhrer MD (Assistant Attending)

Authors
  1. Hans L. Stöhrer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Brookdale Department of Geriatrics and Adult Development, Mount Sinai School of Medicine, New York, NY, 10029, USA

    Rainier P. Soriano MD (Assistant Professor and Director of Medical Student Education), Helen M. Fernandez MD (Assistant Professor and Fellowship Director) & Rosanne M. Leipzig MD, PhD (Professor and Vice Chair of Education) (Assistant Professor and Director of Medical Student Education),  (Assistant Professor and Fellowship Director) &  (Professor and Vice Chair of Education)

  2. ABIM Foundation and American Board of Internal Medicine, Philadelphia, PA, 19106, USA

    Christine K. Cassel MD, MACP (President and CEO) (President and CEO)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Stöhrer, H.L. (2007). Benign Prostatic Hyperplasia. In: Soriano, R.P., Fernandez, H.M., Cassel, C.K., Leipzig, R.M. (eds) Fundamentals of Geriatric Medicine. Springer, New York, NY. https://doi.org/10.1007/978-0-387-32326-8_27

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-32326-8_27

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-32324-4

  • Online ISBN: 978-0-387-32326-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation